Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...

The company's lead candidate, THB335, an oral wild-type KIT inhibitor, has garnered attention from analysts due to its potential to address an untapped area in inflammation and immunology (I&I). Third ...